Nicorandil preserves blood-brain barrier and improves memory impairment in hypertensive rats

Zatiye Ayça Çevikelli Yakut; Büşra Ertaş; Türkan Koyuncuoğlu; Berrak Yeğen; Göksel Şener

Nicorandil preserves blood-brain barrier and improves memory impairment in hypertensive rats

Abstract

In renovascular hypertension (RVH), oxidative stress and inflammation due to high blood pressure and elevated levels of angiotensin 2 are mainly responsible of cerebrovascular complications and impaired cognitive functions. Since the nicorandil has been shown to exert neuroprotective, anti-inflammatory and antioxidant effects, we investigated the effect of nicorandil against vascular dementia and blood brain barrier damage in a rat model of angiotensin-dependent hypertension. Wistar albino rats, were divided as sham-operated control, renovascular hypertension (RVH) and Nicorandil-treated RVH groups. Silver clip was implanted onto the left renal artery. Using the tail-cuff method, blood pressure of rats was measured before the surgery and at the end of the post-surgical 3rd and 12th weeks. Nicorandil (4mg/kg, orally) or vehicle was administered for 9 weeks. Twelve weeks after RVH surgery, a new object recognition test was performed. Following the determination of blood brain barrier integrity, serum samples were taken for the evaluation of proinflammatory cytokines tumor necrosis alpha (TNF-α) and interleukin-1 beta (IL-1β). Levels of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase), as a marker of endothelial damage, were evaluated in the hippocampal tissues. RVH resulted in significant increases in TNF-α and IL-1β levels and decreases in Na+/K+-ATPase levels, along with impairment in blood brain barrier integrity and memory performance. In the nicorandil treatment group, these indices were reversed back to control levels. The present data demonstrated that nicorandil attenuates RVH-induced memory impairment and blood brain barrier damage in rats with RVH.

Keywords

References

[1] Samadian F, Dalili N, Jamalian A. New Insights Into Pathophysiology, Diagnosis, and Treatment of Renovascular Hypertension. Iran J Kidney Dis. 2017; 11(2): 79-89.
[2] Erşahin M, Sehirli O, Toklu HZ, Süleymanoglu S, Emekli-Alturfan E, Yarat A, Tatlidede E, Yeğen BC, Sener G. Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension. J Pineal Res. 2009; 47(1): 97-106. [CrossRef]
[3] Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013; 15(3): 134-136. [CrossRef]
[4] World Health Organization. A global brief on hypertension: silent killer, global public health crisis. http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/2013. [accessed April 21, 2016].
[5] Faconti L, Bruno RM, Ghiadoni L, Taddei S, Virdis A. Ventricular and vascular stiffening in aging and hypertension. Curr Hypertens Rev. 2015; 11: 100–109.
[6] Zafari AM, Ushio-Fukai M, AkersMet al. Role of NADH/ NADPH oxidase-derived H2O2 in angiotensin II–induced vascular hypertrophy. Hypertension. 1998; 32: 488–495. [CrossRef]
[7] Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin-IIinduced but not catecholamine-induced hypertension. Circulation. 1997; 95: 588–593. [CrossRef]
[8] Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000; 101:1722–1728. [CrossRef]

[9] Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPAR alpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002; 40: 866–871. [CrossRef]
[10] Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996; 271: 23317–23321. [CrossRef]
[11] Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001; 38: 581–587. [CrossRef]
[12] Rosenberg GA, Wallin A, Wardlaw JM, Markus HS, Montaner J, Wolfson L, Iadecola C, Zlokovic BV, Joutel A, Dichgans M, Duering M, Schmidt R, Korczyn AD, Grinberg LT, Chui HC, Hachinski V. Consensus statement for diagnosis of subcortical small vessel disease. J Cereb Blood Flow Metab. 2016; 36: 6–25. [CrossRef]
[13] Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med. 2001; 17: 1402–1409. [CrossRef]
[14] Winklewski PJ, Radkowski M, Wszedybyl-Winklewska M & Demkow U. Brain inflammation and hypertension: the chicken or the egg? J Neuroinflammation. 2015; 12, 85. [CrossRef]
[15] Starr J.M, Farrall AJ, Armitage P, McGurn B, and Wardlaw J. Blood-brain barrier permeability in Alzheimer’s disease: a case-control MRI study. Psychiatry Res. 2009; 171, 232–241. [CrossRef]
[16] Taheri S, Gasparovic C, Huisa BN, Adair JC, Edmonds E, Prestopnik J. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke. 2011; 42, 2158–2163. [CrossRef]
[17] de Lores Arnaiz GR, Ordieres MG. Brain Na(+), K(+)-ATPase Activity In Aging and Disease. Int J Biomed Sci. 2014; 10(2):85-102.
[18] Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience. 2004; 129: 1021-1029. [CrossRef]
[19] Masayo Koide, Adrian D. Bonev, Mark T. Nelson, and George C. Wellman. Inversion of neurovascular coupling by subarachnoid blood depends on large conductance Ca2+-activated K+ (BK) channels. PNAS. 2012; 109 (21): 1387-1395 [CrossRef]
[20] Kitazono T, Faraci FM, Taguchi H, Heistad DD. Role of potassium channels in cerebral blood vessels. Stroke. 1995; 26(9): 1713-23. [CrossRef]
[21] Liu FY, Cogan MG. Angiotensin II stimulation of hydrogen ion secretion in the rat early proximal tubule: Modes of action, mechanism, and kinetics. Clin Invest. 1988; 82: 601-607. [CrossRef]
[22] Tarkin JM, Kaski J. Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris. Eur Cardiol. 2018; 13(1):23-28. [CrossRef]
[23] Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther. 1990; 4(4):1075-88. [CrossRef]
[24] Singh P, Gupta S, Sharma B. Melatonin receptor and KATP channel modulation in experimental vascular dementia. Physiol Behav. 2015; 142:66-78. [CrossRef]
[25] Kong J, Ren G, Jia N, Wang Y, Zhang H, Zhang W, Chen B, Cao Y. Effects of nicorandil in neuroprotective activation of PI3K/AKT pathways in a cellular model of Alzheimer's disease. Eur. Neurol. 2013; 70: 233–241. [CrossRef]
[26] Wei XM, Heywood GJ, Di Girolamo N, Thomas PS. Nicorandil inhibits the release of TNFalpha from a lymphocyte cell line and peripheral blood lymphocytes. Int. Immunopharmacol. 2003; 3: 1588. [CrossRef]
[27] Zhao AP, Dong YF, Liu W, Gu J, Sun XL. Nicorandil inhibits inflammasome activation and Toll-like receptor-4 signal transduction to protect against oxygen-glucose deprivation-induced inflammation in BV-2 cells. CNS Neurosci. Ther. 2014; 20: 147–153. [CrossRef]
[28] Heurteaux C, Bertaina V, Widmann C, and Lazdunski M. K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid (3-protein precursor genes and neuronal death in rat hippocampus. Neurobiology. 1993; 90(20):9431-9435. [CrossRef]
[29] Gupta S, Sharma B. Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington's disease, Eur. J. Pharmacol. 2014; 732: 122. [CrossRef]
[30] Horinaka S, Kobayashi N, Yabe A, Asakawa H, Yagi H, Mori Y, Tsubokou Y, Yoshida K. Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction, Cardiovasc. Drugs Ther. 2004; 18: 13–22. [CrossRef]
[31] Cachofeiro V, Miana M, de las Heras N, Martin-Fernandez B, Ballesteros S, Balfagon G, Lahera V. Inflammation: A Link Between Hypertension and Atherosclerosis. Current Hypertension Reviews. 2009; 5, 40-48. [CrossRef]
[32] Lan QX, Mercurius KO, Davies PF. Stimulation of Transcription Factors NFκB and AP1 in Endothelial Cells Subjected to Shear Stress. Biochemical and Biophysical Research Communications. 1994; 201(2): 950-956. [CrossRef]
[33] Li N, Karin M. Is NFkβ the sensor of oxidative stress?. FASEB J. 1999; 13: 1137-43. [CrossRef]
[34] Ashby EL, Kehoe PG. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Opin Investig Drugs. 2013; 22(10): 1229-42. [CrossRef]
[35] Ruiz-Ortega M, Rupérez M, Sánchez-López VEE, Rodríguez-Vita J, Carvajal G, Egido J. Angiotensin II as a novel proinflammatory factor in chronic diseases. Inflammation and Chronic Disease. 2006; 1-25.
[36] Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000; 35: 313. [CrossRef]
[37] Matrougui K, Tanko LB, Loufrani L, Gorny D, Levy BI, Tedgui A, Henrion D. Involvement of Rho-kinase and the actin filament network in angiotensin II-induced contraction and extracellular signal-regulated kinase activity in intact rat mesenteric resistance arteries. Arterioscler Thromb Vasc Biol. 2001; 21: 1288. [CrossRef]
[38] Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor. J Biol Chem. 1996; 271:736–741. [CrossRef]
[39] Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem. 1998; 273(5):2926–2930. [CrossRef]
[40] Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol. 2001; 70(3):317–325. [CrossRef]
[41] Sprague AH, Khalil RA. Inflammatory Cytokines in Vascular Dysfunction and Vascular Disease. Biochem Pharmacol. 2009; 78(6): 539–552. [CrossRef]
[42] Gupta S, Singh P, Sharma B. Neuroprotective Effects of Nicorandil in Chronic Cerebral Hypoperfusion-Induced Vascular Dementia. J Stroke Cerebrovasc Dis. 2016; 25(11):2717-2728. [CrossRef]
[43] Biancardi VC, Son SJ, Ahmadi S, Filosa JA, Stern JE. Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier. Hypertension. 2014; 63(3): 572-9. [CrossRef]
[44] Biancardi VC, Stern JE. Compromised blood–brain barrier permeability: novel mechanism by which circulating angiotensin II signals to sympathoexcitatory centres during hypertension. J Physiol. 2016; 594(6): 1591–1600. [CrossRef]
[45] Fleegal-DeMotta MA, Doghu S, Banks WA. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab. 2009; 29(3): 640-7. [CrossRef]
[46] Setiadi A, Korim WS, Elsaafien K, Yao ST. The role of the blood-brain barrier in hypertension. Experimental Physiology. 2018; 103(3): 337-342. [CrossRef]
[47] Rochfort, KD, Collins LE, Murphy RP, Cummins PM. Downregulation of Blood-Brain Barrier Phenotype by Proinflammatory Cytokines Involves NADPH Oxidase-Dependent ROS Generation: Consequences for Interendothelial Adherens and Tight Junctions. PLoS One. 2014; 9(7): 101815.
[48] de Lores Arnaiz GR, Ordieres MG. Brain Na+, K+-ATPase Activity. In Aging and Disease. Int J Biomed Sci. 2014; 10(2): 85–102. [CrossRef]
[49] Kurauchi Y, Hisatsune A, Seki T, Katsuki H. Na(+), K(+)-ATPase dysfunction causes cerebrovascular endothelial cell degeneration in rat prefrontal cortex slice cultures. Brain Res. 2016; 1644: 249-57. [CrossRef]
[50] Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on Experimental Hypertension I. The production of persistent elevation of the systolic blood pressure by means of renal ischemia. Journal of Experimental Medicine. 1934; 59: 347–379. [CrossRef]
[51] Toklu HZ, Keyer Uysal M, Kabasakal L, Sirvanci S, Ercan F, Kaya M. The Effects of Riluzole on Neurological, Brain Biochemical, and Histological Changes in Early and Late Term of Sepsis in Rats. J Surg Res. 2009; 152: 238-48. [CrossRef]
[52] Kadıoğlu SB. PhD Thesis. The effect of Myrtus communis subsp. communis on cognitive and neuronal functions of postmenopausal diabetic rats. Department of Pharmacology, Faculty of Pharmacy, Marmara University, Haydarpaşa, İstanbul, Turkey, 2017.

Details

Primary Language

English

Subjects

Basic Pharmacology

Journal Section

Research Article

Authors

Zatiye Ayça Çevikelli Yakut This is me
Türkiye

Büşra Ertaş
Türkiye

Türkan Koyuncuoğlu This is me
Türkiye

Berrak Yeğen
Türkiye

Göksel Şener ^*
Türkiye

Publication Date

June 27, 2025

Submission Date

September 10, 2019

Acceptance Date

October 22, 2019

Published in Issue

Year 2019 Volume: 23 Number: 6

IZ

https://izlik.org/JA47TU24CW

Cite

RIS / Bibtex

APA

Çevikelli Yakut, Z. A., Ertaş, B., Koyuncuoğlu, T., Yeğen, B., & Şener, G. (2025). Nicorandil preserves blood-brain barrier and improves memory impairment in hypertensive rats. Journal of Research in Pharmacy, 23(6), 1140-1148. https://izlik.org/JA47TU24CW

AMA

1.Çevikelli Yakut ZA, Ertaş B, Koyuncuoğlu T, Yeğen B, Şener G. Nicorandil preserves blood-brain barrier and improves memory impairment in hypertensive rats. J. Res. Pharm. 2025;23(6):1140-1148. https://izlik.org/JA47TU24CW

Chicago

Çevikelli Yakut, Zatiye Ayça, Büşra Ertaş, Türkan Koyuncuoğlu, Berrak Yeğen, and Göksel Şener. 2025. “Nicorandil Preserves Blood-Brain Barrier and Improves Memory Impairment in Hypertensive Rats”. Journal of Research in Pharmacy 23 (6): 1140-48. https://izlik.org/JA47TU24CW.

EndNote

Çevikelli Yakut ZA, Ertaş B, Koyuncuoğlu T, Yeğen B, Şener G (July 1, 2025) Nicorandil preserves blood-brain barrier and improves memory impairment in hypertensive rats. Journal of Research in Pharmacy 23 6 1140–1148.

IEEE

[1]Z. A. Çevikelli Yakut, B. Ertaş, T. Koyuncuoğlu, B. Yeğen, and G. Şener, “Nicorandil preserves blood-brain barrier and improves memory impairment in hypertensive rats”, J. Res. Pharm., vol. 23, no. 6, pp. 1140–1148, July 2025, [Online]. Available: https://izlik.org/JA47TU24CW

ISNAD

Çevikelli Yakut, Zatiye Ayça - Ertaş, Büşra - Koyuncuoğlu, Türkan - Yeğen, Berrak - Şener, Göksel. “Nicorandil Preserves Blood-Brain Barrier and Improves Memory Impairment in Hypertensive Rats”. Journal of Research in Pharmacy 23/6 (July 1, 2025): 1140-1148. https://izlik.org/JA47TU24CW.

JAMA

1.Çevikelli Yakut ZA, Ertaş B, Koyuncuoğlu T, Yeğen B, Şener G. Nicorandil preserves blood-brain barrier and improves memory impairment in hypertensive rats. J. Res. Pharm. 2025;23:1140–1148.

MLA

Çevikelli Yakut, Zatiye Ayça, et al. “Nicorandil Preserves Blood-Brain Barrier and Improves Memory Impairment in Hypertensive Rats”. Journal of Research in Pharmacy, vol. 23, no. 6, July 2025, pp. 1140-8, https://izlik.org/JA47TU24CW.

Vancouver

1.Zatiye Ayça Çevikelli Yakut, Büşra Ertaş, Türkan Koyuncuoğlu, Berrak Yeğen, Göksel Şener. Nicorandil preserves blood-brain barrier and improves memory impairment in hypertensive rats. J. Res. Pharm. [Internet]. 2025 Jul. 1;23(6):1140-8. Available from: https://izlik.org/JA47TU24CW